Zhitong Finance App News, Xintiandi (301277.SZ) issued an announcement. Recently, the company received the European Pharmacopeia Certificate of Suitability (hereinafter referred to as “CEP Certificate”) for moxifloxacin hydrochloride APIs issued by the European Medicines Quality Administration (hereinafter referred to as “EDQM”). Moxifloxacin hydrochloride is a quinolone antibiotic used to treat infectious diseases caused by pathogens sensitive to this product, such as bacterial sinusitis, acute attacks of bacterial chronic bronchitis, community-acquired pneumonia, simple skin and skin tissue infections, complex intra-abdominal infections, and complex skin and skin tissue infections.

This time, the company's moxifloxacin hydrochloride API obtained the CEP certificate, which indicates that the European regulatory market recognizes and affirms the quality of the API, indicating that the API can be sold in the European market and other regulated markets that recognize the CEP certificate, which has had a positive impact on the company's further enrichment of products and expansion of the international market.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.